Maine legislators pass drug pricing transparency law: 4 things to know

A Maine bill that aims to increase drug pricing transparency became law on April 30, according to a STAT report.

Here are four things to know about the bill.

1. The bill, LD 1406, is sponsored by Maine Sen. Eloise Vitelli, D-Arrowsic.

2. It calls for greater transparency with respect to prescription drug development expenses, according to a Maine Senate news release. It is also meant to be an information source for lawmakers.

3. LD 1406, as amended, directs the Maine Health Data Organization "to collect and report on the top 25 prescription drugs that are the most frequently prescribed in the state, the most costly, and have the highest year-over-year increase in total spending," the release states. The MDHO subsequently must establish a plan for data collection from manufacturers, and provide Maine lawmakers with an annual report on prescription drug prices. Submission of the first report is expected in April 2019.

4. Maine's drug pricing transparency law will take affect in approximately three months after the legislative session ends.


More articles on supply chain:
McKesson adds Medtronic exec as independent director: 4 takeaways
FDA approves first drug for rare form of rickets: 3 things to know
Ascension forms global supply chain company with Australian hospital operator: 8 things to know

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars